Literature DB >> 10319887

Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-nitropropionic acid.

N Nakao1, E Nakai, K Nakai, T Itakura.   

Abstract

We investigated the role of the excitatory afferents from the subthalamic nucleus (STN) in the death of nigral dopamine (DA) neurons after nigrostriatal axon terminal lesions. Nigral DA neurons were detected by use of both tyrosine hydroxylase immunolabeling or retrograde labeling of nigral cells with fluorogold. Sprague-Dawley rats were subjected to unilateral, quinolinic acid-induced destruction of the STN. Sham lesions of the STN were made by injecting phosphate-buffered saline. Two weeks after STN ablation, lesions of nigrostriatal DA neurons were induced by intrastriatal injections of either the mitochondrial toxin 3-nitropropionic acid (3-NP) or the catecholamine toxin 6-hydroxydopamine (6-OHDA). Intrastriatal injections of 3-NP or 6-OHDA caused a progressive loss of nigral tyrosine hydroxylase-positive or fluorogold-labeled DA neurons in a dose-dependent manner. Previous ablation of the STN significantly attenuates the loss of DA neurons in rats receiving 3-NP but not 6-OHDA. Sham lesions of the STN did not affect DA neuron death induced by the toxins. The results indicate that the excitatory inputs from the STN may contribute to the death of nigral DA neurons under a condition of 3-NP-induced metabolic impairment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10319887

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  11 in total

1.  Decreased striatal dopamine release underlies increased expression of long-term synaptic potentiation at corticostriatal synapses 24 h after 3-nitropropionic-acid-induced chemical hypoxia.

Authors:  Garnik Akopian; Cynthia Crawford; M Flint Beal; Maurand Cappelletti; Michael W Jakowec; Giselle M Petzinger; Ling Zheng; Stacey L Gheorghe; Carmela M Reichel; Robert Chow; John P Walsh
Journal:  J Neurosci       Date:  2008-09-17       Impact factor: 6.167

2.  Deep brain stimulation in early Parkinson's disease: enrollment experience from a pilot trial.

Authors:  P D Charles; R M Dolhun; C E Gill; T L Davis; M J Bliton; M G Tramontana; R M Salomon; L Wang; P Hedera; F T Phibbs; J S Neimat; P E Konrad
Journal:  Parkinsonism Relat Disord       Date:  2011-11-21       Impact factor: 4.891

3.  The putative neuroprotective role of dopamine agonists in Parkinson's disease.

Authors:  F Grandas
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 4.  Toxin-induced models of Parkinson's disease.

Authors:  Jordi Bové; Delphine Prou; Céline Perier; Serge Przedborski
Journal:  NeuroRx       Date:  2005-07

5.  Identification of effective features of LFP signal for making closed-loop deep brain stimulation in parkinsonian rats.

Authors:  Sana Amoozegar; Mohammad Pooyan; Mehrdad Roghani
Journal:  Med Biol Eng Comput       Date:  2021-11-13       Impact factor: 2.602

6.  Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation.

Authors:  R Hilker; A T Portman; J Voges; M J Staal; L Burghaus; T van Laar; A Koulousakis; R P Maguire; J Pruim; B M de Jong; K Herholz; V Sturm; W-D Heiss; K L Leenders
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

7.  Pilot study assessing the feasibility of applying bilateral subthalamic nucleus deep brain stimulation in very early stage Parkinson's disease: study design and rationale.

Authors:  David Charles; Christopher Tolleson; Thomas L Davis; Chandler E Gill; Anna L Molinari; Mark J Bliton; Michael G Tramontana; Ronald M Salomon; Chris Kao; Lily Wang; Peter Hedera; Fenna T Phibbs; Joseph S Neimat; Peter E Konrad
Journal:  J Parkinsons Dis       Date:  2012       Impact factor: 5.568

8.  Current approaches to the treatment of Parkinson's disease.

Authors:  Joseph Jankovic; L Giselle Aguilar
Journal:  Neuropsychiatr Dis Treat       Date:  2008-08       Impact factor: 2.570

9.  Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.

Authors:  Thomas Musacchio; Maike Rebenstorff; Felix Fluri; Jonathan M Brotchie; Jens Volkmann; James B Koprich; Chi Wang Ip
Journal:  Ann Neurol       Date:  2017-06-09       Impact factor: 10.422

Review 10.  Neuroprotective Surgical Strategies in Parkinson's Disease: Role of Preclinical Data.

Authors:  Napoleon Torres; Jenny Molet; Cecile Moro; John Mitrofanis; Alim Louis Benabid
Journal:  Int J Mol Sci       Date:  2017-10-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.